Local Drug Delivery System for Cancer
Present technology is related to drug delivery system of anticancer pharmaceutical composition and method of producing same pharmaceutical composition. This technology more specifically related to pharmaceutical composition for delivery of anticancer active ingredient to localized area having solid tumors over an extended period of time. Pharmaceutical composition consists of natural biodegradable polymeric chitosan matrix and anticancer chemotherauptic agent. This pharmaceutical composition has to implant within or immediately adjacent to solid tumors to be treated or the site from where they have been surgically removed. The mentioned pharmaceutical composition can be administered alone or in combination with, either before, simultaneously, or subsequent to, treatment using chemotherapeutic or radiation therapy or surgery, which is released by diffusion or degradation over a period of eight hours. Accordingly, the present invention provides a pharmaceutical composition for preventing or treating solid tumors which consist of natural polymeric matrix, poloxamer and anticancer chemotherapeutic agent/s, optionally along with additives selected from the group consisting of surfactant/s, and plasticizers. What is Novelty The existing anticancer drugs have problem of bioavailability, efficacy, systematic related toxicity and constraints encountered during drug delivery such as brain-blood barrier. To overcome these problems there is need to make efficient delivery of low molecular and high molecular weight drugs. In some of the previous attempts, in order to develop a local drug delivery system based on paclitaxel, a biodegradable chitosan film was attempted .However, effective incorporation of the paclitaxel in the chitosan matrix was not achieved. This was mainly due to the fact that chitosan is only soluble in aqueous acidic solutions where as paclitaxel being a hydrophobic drug, is insoluble under similar conditions. Thus paclitaxel cannot be incorporated in the polymeric chitosan matrix because of their differences in solubility. In earlier research, drug delivery based on paclitaxel and polymeric chitosan matrix with lipid and liposome as carrier also tried but problem still persisted. In case of lipid it was seen that lipids were prone to oxidation and hydrolytic degradation processes which gets further accelerated under heat. Whereas the present technology used poloxamer as a carrier by replacing lipid and liposome and it is seen that this technology overcame the problems of bioavailability, efficacy, systematic related toxicity and constraints encountered during drug delivery such as brain-blood barrier as poloxamer was not prone to oxidation and hydrolytic degradation processes.
Sector: Pharmaceuticals
Country: India
Area of Application: Pharma industry.
Keywords: Drug Delivery, Cancer
Advantages: This drug delivery system overcomes the blood-brain barrier Not produce toxic effects to patients This Pharmaceutical composition is noncytotoxic No side effectsPharmaceutical composition can be delivered with additional chemotherapeutics, antibiotics, antiviral, antinflammatories, cytokines, immunotoxins, antitumor antibodies, anti-angiogenic agents, antiedema, radiosensitizers, Huge market opportunity Consisting polymer chitosan is biodegradable and biocompatible Enhance bioavailability and efficacy
Environmental aspects: Not Applicable
Development Status: Laboratory Model
Legal Protection: Patent
Technical specifications:
Transfer Terms: Technology Licensing
Target Countries: India
Estimated cost (US$):
Upload any relevant document:
Contact Person: SkyQuest Technology Consulting Pvt. Ltd.
Address: 501, Krishna Complex, Opp. Devashish School, Bodakdev
City: Ahmedabad
Country: India
Zip/Pin Code: 380054